In early 2014, Canada’s rules regarding medical marijuana underwent a significant change. While prior to March 31 individuals were able to obtain permission to grow the drug, now only commercial producers licensed by Health Canada are legally able to do so.


Those with permission to use medical marijuana must now go through a registration process with commercial producers that are themselves licensed. And of course, any marijuana growers in the country that are not licensed commercial producers are now subject to law enforcement action.

The requirements to become a licensed commercial producer under the new Marijuana for Medical Purposes Regulations (MMPR) include meeting physical security requirements for areas where cultivation and storage take place, getting personal security clearance and submitting a licensed producer application. Starting materials for licensed marijuana production can come from Health Canada, other licensed producers or importation. Licensed producers may set their own prices and are only permitted to sell dried marijuana — not oils, resins, extracts or edibles.

Below is some information on six of the 13 licensed producers in Canada. Though all but one are private, they deserve a look from investors given that they’ve been successful in getting through a process that many other marijuana hopefuls are trying to navigate.

Bedrocan Canada

Bedrocan Canada is a joint venture between the Netherlands’ Bedrocan and Bedrocan Canada. Its roots date back to 2011, when Bedrocan was invited to Ottawa from the Netherlands to comment on the MMPR. Ultimately, Bedrocan decided that “Canadian producers, patients, and healthcare professionals could benefit” from the knowledge and experience it’s gained from “producing medicinal cannabis in Europe.”

The company stresses on its website that it bases its activities on all applicable laws and regulations, as well as on evidence from scientific studies on the cultivation and medical use of cannabis. It works with researchers from academia, the industry and governments around the world to engage in cannabis research. It also gives manufacturers of pharmaceuticals raw cannabis or extracts to aid in the development of new cannabis-based drugs.

Pricing for all Bedrocan’s strains is $7.50 per gram.

Canna Farms

Established this year, Canna Farms is located in British Columbia and grows its strains in house. Management and production staff have a combined 45 years of industry experience, and the company says its purpose-built facility goes above the standards set by Health Canada.

Canna Farms uses traditional names for its strains so that patients can continue to use the varieties of marijuana that have worked for them in the past. Registration opened June 23, and the company has no waiting list. Credit cards are accepted for payment, with strains priced as low as $1.75 per gram.

CanniMed

CanniMed was established in 2013, and its stated goal is to “help people with chronic and terminal illnesses improve their quality of life when conventional medicine just isn’t enough.” It’s committed to pursuing safety standards and quality by following pharmaceutical manufacturing standards at its growing locations.

Like Bedrocan, CanniMed collaborates with academic institutions and healthcare professionals on research and development. Cannabis produced by Prairie Plant Systems, under contract with CanniMed, has been used in clinical trials that demonstrate the effectiveness of smoking cannabis for chronic pain management. Currently, the company’s strains are being used in other clinical trials as well.

The company’s prices range from $7.50 to $13.50 per gram.

Delta 9 Bio-Tech

Delta 9 Bio-Tech produces organic medical cannabis products in a sustainable manner. One of its aims is to elevate cannabis to the status of a recognized medicine with scientific backing.

The company’s first harvest occurred this summer, and in the future it plans to produce new strains, including some that are high in CBD, or cannabidiol. Delta 9 is at full capacity for registered patients and it intends to implement a compassionate pricing program to subsidize the cost of cannabis for eligible clients who live on disability or have a low level of income.

In the Zone Produce

British Columbia’s In the Zone Produce will not be registering clients until fall 2014 as it currently has no product for sale. When it does start producing it will do so under the supervision of a microbiologist, offering four strains to start off with.

The company is a small, mom-and-pop-style farm and advertises its strains as boutique and premium. A large pool of strains will be available in the future.

Mettrum 

Mettrum, which was incorporated in Ontario in 2012, provides medical marijuana to its clients as well as educational material for patients and providers alike. For instance, it has developed the Mettrum Spectrum, a system that “categorize[s] medical cannabis according to THC potency, as well as CBD levels.” It’s aimed at helping healthcare professionals “more confidently recommend strains that may be appropriate for specific medical conditions.”

On June 18, Mettrum announced that it has entered into a binding letter of intent with Cinaport Acquisition (TSXV:CPQ.H) that will lead to a reverse takeover of Cinaport by shareholders of Mettrum. Five days later the company put new client registrations on hold due to a greater-than-expected number of registrations.

 

Related reading: 

White Paper — Establishing a Medical Marijuana Business: Top Business and Regulatory Issues

  • Company surpassed 5,600 patient prescriptions for its medical cannabis products in Colombia . Prescriptions filled increased over 450% in Q3 2020 over Q2 2020
  • Khiron declared a National Strategic Project by the Government of Colombia , simplifying and accelerating administration and processes for the Company in executing strategic projects in Colombia and for export
  • Subsequent to the quarter, the Company completed a bought deal financing on November 26, 2020 , selling 32,200,000 units at a price of $0.45 per unit for aggregate gross proceeds of $14,490,000 CAD
  • Khiron signed partnerships with 15 clinics and health centres in Colombia , extending education and sales reach further across the country
  • As a result of the Company’s Doctor Zerenia TM telehealth platform more than 25% of the Company’s medical cannabis prescriptions came from outside of Bogota , expanding geographic presence of its Colombian clinics
  • Company achieved first sales of High CBD medical cannabis through private pharmacies in Peru . Additional approval received from Peru’s drug regulatory authority for Company’s High THC cannabis, with first prescriptions anticipated in Q1 2021
  • Expanded medical cannabis E-Learning platform to UK market in partnership with Medical Cannabis Clinicians Society (“MCCS”)
  • Entered an exclusive partnership with Rappi SAS, Latin America’s largest home multi-vertical app platform to distribute the Company’s CPG product portfolio, introducing Kuida products to Rappi users across the LatAm region
  • Signed agreement to distribute the Company’s Kuida TM CBD skincare brand through pharmacy, beauty retail and online markets serving the Hong Kong territory, with first orders expected in Q4 2020
  • Prudent cash use of $5 million in Q3 2020, compared with $4 million in Q2 2020, $12 million in Q1 2020 and $10 million in Q4 2019

 Khiron Life Sciences Corp. (“Khiron” or the “Company”) (TSXV: KHRN ), (OTCQX: KHRNF), ( Frankfurt : A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe announced today its financial results for the quarter ended September 30, 2020 . These filings are available for review on the Company’s SEDAR profile at www.sedar.com All financial information in this press release is reported in Canadian dollars, unless otherwise indicated.

Keep reading... Show less
  • Q3 Systemwide Pro Forma Revenue increased 18% quarter-over-quarter to $22.3 million , 170% year-over-year – Company became cash flow positive from operations in August
  • Company sale leaseback transaction with Innovative Industrial Properties scheduled to close within two weeks. As a result of close, together with proceeds from the recently closed bought deal financing, the Company will have $16 million of cash and $43 million in long-term debt
  • Company is in the process of acquiring acreage to construct up to 210,000 square feet of flowering canopy and supporting manufacturing facility in Cook County, Illinois to exponentially increase capacity in state
  • Initial guidance for 2021 with Systemwide Pro Forma Revenue of $170 -180 million and Adjusted EBITDA of $40 -50 million
  • The Company’s existing projects at maturity represent a long-term revenue and EBITDA opportunity upwards of $650 million and $250 million

4Front Ventures Corp. (CSE: FFNT) (OTCQX: FFNTF) (” 4Front ” or the ” Company “) today announced its financial results for the third quarter of 2020. All financial information is presented in U.S. dollars unless otherwise indicated.

Third Quarter 2020 Financial Results Highlights

Keep reading... Show less
  • Q3 Systemwide Pro Forma Revenue increased 18% quarter-over-quarter to $22.3 million , 170% year-over-year – Company became cash flow positive from operations in August
  • Company sale leaseback transaction with Innovative Industrial Properties scheduled to close within two weeks. As a result of close, together with proceeds from the recently closed bought deal financing, the Company will have $16 million of cash and $43 million in long-term debt
  • Company is in the process of acquiring acreage to construct up to 210,000 square feet of flowering canopy and supporting manufacturing facility in Cook County, Illinois to exponentially increase capacity in state
  • Initial guidance for 2021 with Systemwide Pro Forma Revenue of $170 -180 million and Adjusted EBITDA of $40 -50 million
  • The Company’s existing projects at maturity represent a long-term revenue and EBITDA opportunity upwards of $650 million and $250 million

4Front Ventures Corp. (CSE: FFNT) (OTCQX: FFNTF) (” 4Front ” or the ” Company “) today announced its financial results for the third quarter of 2020. All financial information is presented in U.S. dollars unless otherwise indicated.

Third Quarter 2020 Financial Results Highlights

Keep reading... Show less

Shareholders with losses exceeding $50,000 are encouraged to contact the firm

The Law Offices of Frank R. Cruz reminds investors of the upcoming December 1, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Aurora Cannabis, Inc. (“Aurora” or the “Company”) (NYSE: ACB ) securities between February 13, 2020 and September 4, 2020 , inclusive (the “Class Period”).

Keep reading... Show less

Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe” or the “Company”) is pleased to announce the launch of preclinical research studies using psilocybin and N-Acetylcysteine (“NAC”) for the treatment of mild traumatic brain injuryconcussion (“mTBI”) with post-traumatic stress disorder (“PTSD”). The study is in collaboration with a multidisciplinary team of scientists and physicians at the University of Miami Miller School of Medicine under the lead of Michael E. Hoffer, M.D., professor of otolaryngology and neurological surgery.

NAC has been shown to be safe and efficacious in a phase I human clinical study in treating military personnel who had suffered mTBI. The initial research focus is to demonstrate the safety and efficacy of the combination of psilocybin and NAC using broadly accepted rodent models. Final results are expected in 2021. Once this is established, more specific work can examine dose response, medicine uptake, and medicine levels. The research team at the Miller School of Medicine has conducted prior studies involving NAC with mTBI and has a license from the United States Drug Enforcement Administration to conduct research using Schedule I controlled substances, which includes psilocybin.

Keep reading... Show less